四環醫藥(00460.HK)治療十二指腸潰瘍創新藥獲內地批准上市

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

四環醫藥(00460.HK)治療十二指腸潰瘍創新藥獲內地批准上市

阿思達克 06-26 12:17

四環醫藥(00460.HK)公布，集團旗下非全資附屬軒竹生物自主研發的質子泵抑制劑(PPI)安奈拉唑鈉腸溶片，獲國家藥監局頒發的藥品註冊批件，用於治療十二指腸潰瘍。是軒竹生物首個獲批上市的藥物。

四環醫藥(00460.HK)

Relevant Stocks

四環醫藥(00460.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

四環醫藥(00460.HK)治療十二指腸潰瘍創新藥獲內地批准上市

Services

About Us

Agreement Statement